{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:02:08Z","timestamp":1790226128813,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Short-term prevention (STP) is a targeted treatment approach to minimize migraine attacks during specific, time-limited periods. Because migraine disproportionately affects women, this study evaluated sex-related differences in the context of rimegepant for STP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cross-sectional observational study collected real-world data via an online survey. Eligible subjects were US residents aged \u226518\u202fyears with self-reported episodic or chronic migraine, receiving rimegepant, initiated \u22653\u202fmonths, and taken within 30\u202fdays of survey completion. Reported\n                      <jats:italic>p<\/jats:italic>\n                      values are nominal (unadjusted).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 425 adults, 152 used rimegepant for STP (female,\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f98 [64.5%]; male,\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f54 [35.5%]). Women were more likely than men to use rimegepant for STP due to doctor recommendation (69.4% vs. 48.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.014), frequency (43.9% vs. 25.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.036), and severity of attacks (43.9% vs. 22.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.008). In women and men, stress (women, 74.5%; men, 59.3%), disruptive sleeping patterns (women, 53.1%; men, 35.2%), and noise (women, 48.0%; men, 35.2%) were the most common factors provocative of a migraine attack. Across sexes, \u226573% were \u201csatisfied\u201d to \u201cextremely satisfied\u201d with rimegepant for STP, men reported numerically higher levels of satisfaction than women with taking rimegepant as an STP treatment one time (94.4% [17\/18] vs. 73.0% [27\/37],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.08).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights how migraine differentially affects women and men. Subtle variations by sex in factors provocative of a migraine attack and reasons for rimegepant use were observed. Regardless of sex, rimegepant has potential for STP of migraine. Women and men reported high levels of satisfaction with rimegepant for STP when taken as needed, every other day, or every day.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1901123","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:36:17Z","timestamp":1790224577000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States"],"prefix":"10.3389","volume":"17","author":[{"given":"Teshamae","family":"Monteith","sequence":"first","affiliation":[{"name":"University of Miami Health System","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Pfizer, Inc.","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Pfizer, Inc.","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine C.","family":"Maculaitis","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"McCaig","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemin","family":"Chen","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Abraham","sequence":"additional","affiliation":[{"name":"Pfizer, Ltd.","place":["Surrey, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Fajardo","sequence":"additional","affiliation":[{"name":"Pfizer, Inc.","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dai","sequence":"additional","affiliation":[{"name":"Pfizer, Inc.","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Medstar Georgetown University Hospital","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","article-title":"Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom","volume":"19","author":"Vo","year":"2018","journal-title":"J Headache Pain"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1468-2982.2008.01666.x","article-title":"Cumulative lifetime migraine incidence in women and men","volume":"28","author":"Stewart","year":"2008","journal-title":"Cephalalgia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10072-020-04643-8","article-title":"Gender-related differences in migraine","volume":"41","author":"Allais","year":"2020","journal-title":"Neurol Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/head.12150","article-title":"Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American migraine prevalence and prevention (AMPP) study","volume":"53","author":"Buse","year":"2013","journal-title":"Headache"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","article-title":"Migraine in America symptoms and treatment (MAST) study: baseline study methods, treatment patterns, and gender differences","volume":"58","author":"Lipton","year":"2018","journal-title":"Headache"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/ene.15778","article-title":"Sex differences in clinical characteristics of migraine and its burden: a population-based study","volume":"30","author":"Chalmer","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s10194-025-02083-3","article-title":"Migraine through puberty and menopausal transition-data from the population-based Norwegian women and health study (NOWAC)","volume":"26","author":"Bugge","year":"2025","journal-title":"J Headache Pain"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11916-018-0731-3","article-title":"A critical exploration of migraine as a health disparity: the imperative of an equity-oriented, intersectional approach","volume":"22","author":"Befus","year":"2018","journal-title":"Curr Pain Headache Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"17455057251376878","DOI":"10.1177\/17455057251376878","article-title":"Understanding migraine throughout a woman's life and the role of calcitonin gene-related peptide: a narrative review","volume":"21","author":"Kuruvilla","year":"2025","journal-title":"Womens Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41582-021-00544-2","article-title":"Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP","volume":"17","author":"Krause","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3331024231170807","DOI":"10.1177\/03331024231170807","article-title":"Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study","volume":"43","author":"Ashina","year":"2023","journal-title":"Cephalalgia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10194-021-01336-1","article-title":"Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study","volume":"22","author":"MaassenVanDenBrink","year":"2021","journal-title":"J Headache Pain"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clinthera.2022.01.006","article-title":"Impact of baseline characteristics on the efficacy and safety of eptinezumab in patients with migraine: subgroup analyses of PROMISE-1 and PROMISE-2","volume":"44","author":"Martin","year":"2022","journal-title":"Clin Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"774341","DOI":"10.3389\/fneur.2021.774341","article-title":"Gender differences in 3-month outcomes of erenumab treatment-study on efficacy and safety of treatment with erenumab in men","volume":"12","author":"Ornello","year":"2021","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3331024251320610","DOI":"10.1177\/03331024251320610","article-title":"Efficacy of ubrogepant and atogepant in males and females with migraine: a secondary analysis of randomized clinical trials","volume":"45","author":"Goadsby","year":"2025","journal-title":"Cephalalgia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3331024241238153","DOI":"10.1177\/03331024241238153","article-title":"Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex","volume":"44","author":"Porreca","year":"2024","journal-title":"Cephalalgia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/0333102420974362","article-title":"Sex differences in prevalence of migraine trigger factors: a cross-sectional study","volume":"41","author":"van Casteren","year":"2021","journal-title":"Cephalalgia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/head.14479","article-title":"Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panel","volume":"63","author":"Graf","year":"2023","journal-title":"Headache"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/head.14828","article-title":"Evaluating the use of paracetamol to prevent fasting headache during the first week of Ramadan: a randomized, open-label, clinical trial","volume":"64","author":"Almohammed","year":"2024","journal-title":"Headache"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1526-4610.2011.01993.x","article-title":"Prophylactic etoricoxib is effective in preventing \u201cfirst of Ramadan\u201d headache: a placebo-controlled double-blind and randomized trial of prophylactic etoricoxib for ritual fasting headache","volume":"52","author":"Drescher","year":"2012","journal-title":"Headache"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1526-4610.2010.01827.x","article-title":"Frovatriptan as preemptive treatment for fasting-induced migraine","volume":"51","author":"Latsko","year":"2011","journal-title":"Headache"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1212\/01.wnl.0000134620.30129.d6","article-title":"A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine","volume":"63","author":"Silberstein","year":"2004","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s10194-025-02185-y","article-title":"Short-term prevention of perimenstrual migraine with rimegepant","volume":"26","author":"Frank","year":"2025","journal-title":"J Headache Pain"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/life14091146","article-title":"Medication-overuse headache: update on management","volume":"14","author":"Koonalintip","year":"2024","journal-title":"Life"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/14737175.2024.2434079","article-title":"Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence","volume":"24","author":"Edvinsson","year":"2024","journal-title":"Expert Rev Neurother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3331024231179131","DOI":"10.1177\/03331024231179131","article-title":"A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants","volume":"43","author":"Bertz","year":"2023","journal-title":"Cephalalgia"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3331024251355947","DOI":"10.1177\/03331024251355947","article-title":"A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine","volume":"45","author":"Alsaadi","year":"2025","journal-title":"Cephalalgia"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737175.2020.1693265","article-title":"Approaching the appropriate pharmacotherapy of menstrual migraine","volume":"20","author":"Martelletti","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"ref30","first-page":"S46","article-title":"Management of migraine: an algorithmic approach","volume":"55","author":"Silberstein","year":"2000","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/head.13314","article-title":"Assessing physician-patient dialogues about chronic migraine during routine office visits","volume":"58","author":"Buse","year":"2018","journal-title":"Headache"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e1326","DOI":"10.1212\/WNL.0000000000200887","article-title":"Association of a cyclical migraine phenotype with disease progression: a 1-year time series analysis","volume":"99","author":"Gallardo","year":"2022","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40120-025-00720-2","article-title":"Menopause, perimenopause, and migraine: understanding the intersections and implications for treatment","volume":"14","author":"Waliszewska-Prosol","year":"2025","journal-title":"Neurol Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/medicina57080735","article-title":"Headache associated with sexual activity-a narrative review of literature","volume":"57","author":"Scislicki","year":"2021","journal-title":"Medicina"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11916-024-01312-9","article-title":"Anxiety disorders, anxious symptomology and related behaviors associated with migraine: A narrative review of prevalence and impact","volume":"29","author":"Raudenska","year":"2025","journal-title":"Curr Pain Headache Rep"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/head.12561","article-title":"The role of fear of pain in headache","volume":"55","author":"Black","year":"2015","journal-title":"Headache"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11916-020-00865-9","article-title":"Fear, avoidance, and disability in headache disorders","volume":"24","author":"Rogers","year":"2020","journal-title":"Curr Pain Headache Rep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-018-0909-4","article-title":"Migraine and cluster headache - the common link","volume":"19","author":"Vollesen","year":"2018","journal-title":"J Headache Pain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1901123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:36:24Z","timestamp":1790224584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1901123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":38,"alternative-id":["10.3389\/fneur.2026.1901123"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1901123","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1901123"}}